Method for preparing nolamycin key intermediate by using continuous flow technology
By using continuous flow technology to prepare Lolamicin intermediates in microchannel reactors, the problems of harsh reaction conditions and complex purification processes in the prior art are solved, and efficient and safe intermediate preparation is achieved, which is suitable for industrial production.
Patent Information
- Application Number
- CN202411211435.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-08
AI Technical Summary
In the existing preparation method of Lolamicin intermediate 5, the reaction conditions are harsh, the purification process is complex, and the yield is low, making it difficult to achieve industrial production.
The key intermediates of Lolamicin are prepared by continuous flow technology. By efficient mixing and mass transfer in the microchannel reactor, the deep-cold reaction is avoided, the reaction temperature and selectivity is improved, and tetrahydrofuran is used as a solvent to perform acid washing and pH adjustment. Organic extraction, concentration and recrystallization are used to obtain high-purity intermediates.
The target product conversion rate is improved to more than 90%, the by-product content is controlled below 0.1%, the purity is more than 99%, and the molar yield is more than 85%, which simplifies the purification process, reduces production costs and risks, and is suitable for industrial production. .
Smart Images

Figure CN118908885A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of drug intermediate synthesis, and relates to the preparation of a key intermediate of a novel antibiotic Lolamicin, 3-[3-[2-(4-2,6-dimethylpyridinyl)-acetyl]-benzyloxy]-benzonitrile, and specifically relates to a method for preparing the intermediate by using a continuous flow technology. Background Art
[0002] Lolamicin, Chinese name: Loramicin, Lolamicin, the structural formula is as follows:
[0003]
[0004] Lolamicin is a new type of antibiotic designed and developed by scientists that can deal with clinically difficult-to-treat multidrug-resistant Gram-negative pathogens. Animal experiments have shown that while treating pathogenic bacteria infections, this antibiotic can also protect beneficial bacteria in the intestines and prevent secondary infections.
[0005] Related studies have shown that Lolamicin is active against more than 130 multidrug-resistant clinical isolates, has shown efficacy in a variety of acute pneumonia and sepsis infection mouse models, and protects the intestinal microbiome of mice from secondary infection with Clostridium difficile. Lolamicin selectively kills pathogenic Gram-negative bacteria as a result of low sequence homology between pathogenic bacteria and commensal bacteria. Lolamicin can be used to study infections caused by Gram-negative pathogens.
[0006] As a new compound, there are few publicly reported synthetic routes for Lolamicin. Only patent WO2023091873 discloses a synthetic route, which is as follows:
[0007]
[0008] Specific process reaction process: 3-hydroxybenzoic acid methyl ester is used as the starting material, and Lolamicin is obtained through condensation, hydrolysis, amidation, ketoalkylation, methylation, and cyclization reactions.
[0009] In the process of synthesizing intermediate 5 (3-[3-[2-(4-2,6-dimethylpyridinyl)-acetyl]-benzyloxy]-benzonitrile) from intermediate 4 (3-cyano-3-(benzyloxy)-N-methoxy-N-methylbenzamide), the synthetic reaction selectivity is poor, a large amount of by-product 5A is generated, and separation and purification are difficult. Column chromatography technology must be used for product purification. The reaction conditions are also relatively harsh, and the reaction temperature needs to be below -78°C. The molar yield of the product is also low, only about 40%. The above problems make it difficult to achieve industrial production of this process.
[0010] Therefore, it is necessary to find a simple, efficient and easy-to-commercially produce continuous synthesis process of intermediate 5 (3-[3-[2-(4-2,6-dimethylpyridinyl)-acetyl]-benzyloxy]-benzonitrile) Summary of the invention
[0011] The technical problem to be solved by the present invention is to overcome the defects of harsh reaction conditions, complex purification process, low yield and the like in the preparation method of Lolamicin intermediate 5 in the prior art, and provide a method for preparing the key intermediate of Lolamicin using continuous flow technology. Compared with the existing method, the present invention avoids the deep cold reaction and column chromatography purification process, improves the selectivity of the synthetic reaction, the conversion rate of the target product is above 90%, and the content of the by-product 5A is controlled below 0.1%. The purity of the prepared intermediate 5 is above 99%, the molar yield is above 85%, there is no amplification effect, and it is conducive to commercial large-scale production.
[0012] The present invention solves the above technical problems through the following technical solutions:
[0013] A method for preparing a key intermediate of Lolamicin using continuous flow technology comprises the following steps: using a mixed solution made of 2,4,6-trimethylpyridine, a non-nucleophilic strong base and a solvent as material one, and using a mixed solution made of Lolamicin intermediate 4 and a solvent as material two; passing material one and material two into a continuous flow reactor for reaction to obtain Lolamicin intermediate 5; the synthesis route thereof is as follows:
[0014]
[0015] Wherein, the Lolamicin intermediate 4 is 3-cyano-3-(benzyloxy)-N-methoxy-N-methylbenzamide. The Lolamicin intermediate 5 is 3-[3-[2-(4-2,6-dimethylpyridinyl)-acetyl]-benzyloxy]-benzonitrile.
[0016] In some embodiments, the non-nucleophilic strong base preferably includes at least one of lithium hexamethyldisilazide (LiHMDS), lithium diisopropylamide (LDA), etc., and more preferably lithium hexamethyldisilazide.
[0017] In some embodiments, the molar ratio of the Lolamicin intermediate 4 to the 2,4,6-trimethylpyridine is preferably 1:1.1-1.3.
[0018] In some embodiments, the molar ratio of the Lolamicin intermediate 4 to the non-nucleophilic strong base is preferably 1:1.1-1.5.
[0019] In some embodiments, the solvent preferably includes at least one of tetrahydrofuran (THF), toluene, etc., and more preferably tetrahydrofuran (THF).
[0020] In some embodiments, the mass volume ratio of 2,4,6-trimethylpyridine to the solvent in material one is preferably 1 g:10-30 mL, more preferably 1 g:15 mL.
[0021] In some embodiments, the mass volume ratio of Lolamicin intermediate 4 to the solvent in material 2 is preferably 1 g:15-30 mL, more preferably 1 g:20 mL.
[0022] In some embodiments, the flow rate of material 1 is preferably 10 mL / min to 100 mL / min, more preferably 20 mL / min. The flow rate of material 2 is preferably 10 mL / min to 100 mL / min, more preferably 60 mL / min.
[0023] In some embodiments, the reaction temperature is preferably -15° C. to 0° C., more preferably -10° C. to -5° C. The reaction time is preferably 10 to 50 seconds.
[0024] In some embodiments, the method further comprises the following steps: washing the obtained reaction solution with acid, adjusting the pH to neutral, and extracting with an organic solvent; concentrating the organic phase, recrystallizing, filtering and drying to obtain the intermediate 5. The acid is preferably an acetic acid solution; the reagent used to adjust the pH is preferably NaHCO3; the organic solvent is preferably dichloromethane; and the recrystallization is preferably ethanol-water recrystallization.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] (1) The present invention provides a method for preparing a key intermediate of loramycin using continuous flow technology. Compared with conventional synthesis reaction devices, the present invention innovatively adopts continuous flow in a microchannel reactor to synthesize the key intermediate of loramycin, making full use of the high mixing efficiency and excellent mass transfer and heat transfer performance of the continuous flow reactor, thereby avoiding the deep cold reaction (-78°C) in the existing synthesis reaction, so that the reaction can be carried out at -15°C to 0°C, greatly improving the reaction temperature, making the reaction conditions more mild, and solving the problems of high by-product generation rate, low target product yield, and complex separation and purification process while reducing production costs. At the same time, the present invention has a short reaction time and no amplification effect, which greatly improves the safety of production. Due to the rapid reaction and high selectivity, the conversion rate of the target product is as high as more than 90%, and the content of the by-product 5A is as low as less than 0.1%. The intermediate 5 obtained by the post-treatment steps of neutralization, extraction, concentration, recrystallization, drying, etc. of the reaction solution has a purity of more than 99.0% and a molar yield of more than 85%, which is greatly improved compared with the molar yield of about 40% in the prior art. After the reaction, the present invention has a high target product content and a low by-product content, thus avoiding the cumbersome purification process such as column chromatography after the existing synthesis reaction, and is more suitable for industrial production.
[0027] (2) The present invention uses THF (tetrahydrofuran) as the reaction solvent, which is suitable for a microchannel reactor made of glass.
[0028] (3) The reaction time of the present invention is greatly shortened from 2-3 hours in a kettle reaction to 10-50 seconds.
[0029] (4) The reaction process of the present invention has no scale-up effect, and provides a new continuous flow reaction method for preparing Lolamicin intermediate 5 from Lolamicin intermediate 4.
[0030] (5) The present invention utilizes continuous flow technology to solve the problems of low production efficiency, poor product selectivity, low purity, and high risk in traditional kettle reactions, and can achieve continuous automated operation, with the advantages of high yield and good safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 The present invention is a process flow chart for preparing Lolamicin intermediate 5 using continuous flow technology.
[0032] Figure 2 This is the HPLC spectrum of Lolamicin intermediate 5 prepared in Example 1 of the present invention. DETAILED DESCRIPTION
[0033] The present invention will be further described below in conjunction with the accompanying drawings and embodiments, but the embodiments of the present invention are not limited thereto.
[0034] The process flow of preparing Lolamicin intermediate 5 using continuous flow technology provided by the present invention is as follows: Figure 1 shown.
[0035] In the following examples, the experimental methods without specific conditions are operated according to conventional methods and conditions. Unless otherwise specified, the raw materials are obtained through commercial channels or existing technologies; the continuous flow reactor uses a high-throughput microchannel reactor G1 model, Corning Incorporated, USA.
[0036] Example 1: Preparation of 3-[3-[2-(4-2,6-dimethylpyridinyl)-acetyl]-benzyloxy]-benzonitrile
[0037] 2,4,6-trimethylpyridine (48.4 g, 0.4 mol) and lithium hexamethyldisilazide (73.5 g, 0.44 mol) were dissolved in tetrahydrofuran (730 mL) to prepare liquid material one, and the liquid material one was introduced into a precooler through flow path one at a flow rate of 20 mL / min using a metering pump and precooled to the reaction temperature, the reaction temperature being -5°C; Lolamicin intermediate 4 (100 g, 0.338 mol) was dissolved in tetrahydrofuran (2000 mL) to prepare liquid material two, and the liquid material two was introduced into a precooler through flow path two at a flow rate of 60 mL / min using a metering pump and precooled to the reaction temperature, the reaction temperature being -5°C.
[0038] After precooling, the two liquid materials are simultaneously introduced into a microreactor precooled to a reaction temperature of -5°C at the original flow rate, and flow into a neutralization extraction tank after staying for 30 seconds. The reaction solution is washed with 30% acetic acid, the pH is adjusted to neutral with NaHCO3, extracted three times with dichloromethane, and the organic phases are combined. The organic phase is transferred to a concentration crystallization tank, concentrated under reduced pressure at room temperature, recrystallized from ethanol-water, filtered and vacuum dried to obtain 3-[3-[2-(4-2,6-dimethylpyridyl)-acetyl]-benzyloxy]-benzonitrile, with a liquid chromatography purity of 99.2%, a by-product 5A of 0.03%, and a molar yield of 87.8%.
[0039] Example 2: Preparation of 3-[3-[2-(4-2,6-dimethylpyridinyl)-acetyl]-benzyloxy]-benzonitrile
[0040] 2,4,6-trimethylpyridine (48.4 g, 0.4 mol) and lithium diisopropylamide (47 g, 0.44 mol) were dissolved in tetrahydrofuran (730 mL) to prepare liquid material one, and the liquid material one was introduced into a precooler through flow path one at a flow rate of 20 mL / min using a metering pump and precooled to the reaction temperature, the reaction temperature being -5°C; Lolamicin intermediate 4 (100 g, 0.338 mol) was dissolved in tetrahydrofuran (2000 mL) to prepare liquid material two, and the liquid material two was introduced into a precooler through flow path two at a flow rate of 60 mL / min using a metering pump and precooled to the reaction temperature, the reaction temperature being -5°C.
[0041] After precooling, the two liquid materials are simultaneously introduced into a microreactor precooled to a reaction temperature of -5°C at the original flow rate, and flow into a neutralization extraction tank after staying for 30 seconds. The reaction solution is washed with 30% acetic acid, the pH is adjusted to neutral with NaHCO3, extracted three times with dichloromethane, and the organic phases are combined. The organic phase is transferred to a concentration crystallization tank, concentrated under reduced pressure at room temperature, recrystallized from ethanol-water, filtered and vacuum dried to obtain 3-[3-[2-(4-2,6-dimethylpyridyl)-acetyl]-benzyloxy]-benzonitrile, with a liquid chromatography purity of 99.0%, a byproduct 5A of 0.06%, and a molar yield of 86.3%.
[0042] Example 3: Preparation of 3-[3-[2-(4-2,6-dimethylpyridinyl)-acetyl]-benzyloxy]-benzonitrile
[0043] 2,4,6-trimethylpyridine (48.4 g, 0.4 mol) and lithium hexamethyldisilazide (85 g, 0.5 mol) were dissolved in tetrahydrofuran (730 mL) to prepare liquid material one, and the liquid material one was introduced into a precooler through flow path one at a flow rate of 20 mL / min using a metering pump and precooled to the reaction temperature, the reaction temperature being -10°C; Lolamicin intermediate 4 (100 g, 0.338 mol) was dissolved in tetrahydrofuran (2000 mL) to prepare liquid material two, and the liquid material two was introduced into a precooler through flow path two at a flow rate of 60 mL / min using a metering pump and precooled to the reaction temperature, the reaction temperature being -10°C.
[0044] After precooling, the two liquid materials are simultaneously introduced into a microreactor precooled to a reaction temperature of -10°C at the original flow rate, and flow into a neutralization extraction tank after staying for 50 seconds. The reaction solution is washed with 30% acetic acid, the pH is adjusted to neutral with NaHCO3, extracted three times with dichloromethane, and the organic phases are combined. The organic phase is transferred to a concentration crystallization tank, concentrated under reduced pressure at room temperature, recrystallized from ethanol-water, filtered and vacuum dried to obtain 3-[3-[2-(4-2,6-dimethylpyridyl)-acetyl]-benzyloxy]-benzonitrile, with a liquid chromatography purity of 99.5%, a byproduct 5A of 0.02%, and a molar yield of 87.0%.
[0045] Example 4: Preparation of 3-[3-[2-(4-2,6-dimethylpyridinyl)-acetyl]-benzyloxy]-benzonitrile
[0046] 2,4,6-trimethylpyridine (48.4 g, 0.4 mol) and lithium diisopropylamide (47 g, 0.44 mol) were dissolved in tetrahydrofuran (730 mL) to prepare liquid material one, and the liquid material one was introduced into a precooler through flow path one at a flow rate of 20 mL / min using a metering pump and precooled to the reaction temperature, the reaction temperature being -10°C; Lolamicin intermediate 4 (100 g, 0.338 mol) was dissolved in tetrahydrofuran (2000 mL) to prepare liquid material two, and the liquid material two was introduced into a precooler through flow path two at a flow rate of 60 mL / min using a metering pump and precooled to the reaction temperature, the reaction temperature being -10°C.
[0047] After precooling, the two liquid materials are simultaneously introduced into a microreactor precooled to a reaction temperature of -10°C at the original flow rate, and flow into a neutralization extraction tank after staying for 50 seconds. The reaction solution is washed with 30% acetic acid, the pH is adjusted to neutral with NaHCO3, extracted three times with dichloromethane, and the organic phases are combined. The organic phase is transferred to a concentration crystallization tank, concentrated under reduced pressure at room temperature, recrystallized from ethanol-water, filtered, and vacuum dried to obtain 3-[3-[2-(4-2,6-dimethylpyridyl)-acetyl]-benzyloxy]-benzonitrile, with a liquid chromatography purity of 99.1%, a byproduct 5A of 0.04%, and a molar yield of 86.1%.
[0048] Example 5: Preparation of 3-[3-[2-(4-2,6-dimethylpyridinyl)-acetyl]-benzyloxy]-benzonitrile
[0049] 2,4,6-trimethylpyridine (48.4 g, 0.4 mol) and lithium diisopropylamide (47 g, 0.44 mol) were dissolved in tetrahydrofuran (730 mL) to prepare liquid material one, and the liquid material one was introduced into a precooler through flow path one at a flow rate of 20 mL / min using a metering pump and precooled to the reaction temperature, and the reaction temperature was 5°C; Lolamicin intermediate 4 (100 g, 0.338 mol) was dissolved in tetrahydrofuran (2000 mL) to prepare liquid material two, and the liquid material two was introduced into a precooler through flow path two at a flow rate of 60 mL / min using a metering pump and precooled to the reaction temperature, and the reaction temperature was 5°C.
[0050] After precooling, the two liquid materials are simultaneously introduced into a microreactor precooled to a reaction temperature of 5°C at the original flow rate, and flow into a neutralization extraction tank after staying for 50 seconds. The reaction solution is washed with 30% acetic acid, the pH is adjusted to neutral with NaHCO3, extracted three times with dichloromethane, and the organic phases are combined. The organic phase is transferred to a concentration crystallization tank, concentrated under reduced pressure at room temperature, recrystallized with ethanol-water, filtered and vacuum dried to obtain 3-[3-[2-(4-2,6-dimethylpyridyl)-acetyl]-benzyloxy]-benzonitrile, with a liquid chromatography purity of 96.3%, a by-product 5A of 1.2%, and a molar yield of 75.8%.
[0051] The above embodiments are only used to help illustrate the present invention. The implementation methods of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A method for preparing a key intermediate of loramycin using continuous flow technology, It is characterized in that The following steps are involved: A mixed solution of 2,4,6-trimethylpyridine, a non-nucleophilic strong base and a solvent is used as material 1, and a mixed solution of loramycin intermediate 4 and a solvent is used as material 2; the materials 1 and 2 are introduced into a continuous flow reactor for reaction to obtain loramycin intermediate 5; The structural formula of the loramycin intermediate 4 is The structural formula of the loramycin intermediate 5 is 2. The method for preparing a key intermediate of loramycin using continuous flow technology according to claim 1, Features: The non-nucleophilic strong base includes at least one of lithium hexamethyldisilazide and lithium diisopropylamide.
3. The method for preparing a key intermediate of loramycin using continuous flow technology according to claim 1, Features: The molar ratio of the loramycin intermediate 4 to the non-nucleophilic strong base is 1:1.1-1.
5.
4. The method for preparing a key intermediate of loramycin using continuous flow technology according to claim 1, Features: The molar ratio of the loramycin intermediate 4 to the 2,4,6-trimethylpyridine is 1:1.1-1.
3.
5. The method for preparing a key intermediate of loramycin using continuous flow technology according to claim 1, Features: The solvent includes at least one of tetrahydrofuran and toluene.
6. The method for preparing a key intermediate of loramycin using continuous flow technology according to claim 1, Features: The mass volume ratio of 2,4,6-trimethylpyridine to the solvent in material one is 1 g:10-30 mL; the mass volume ratio of loramycin intermediate 4 to the solvent in material two is 1 g:15-30 mL.
7. The method for preparing a key intermediate of loramycin using continuous flow technology according to claim 1, Features: The flow rate of material one is 10mL / min~100mL / min, and the flow rate of material two is 10mL / min~100mL / min.
8. The method for preparing a key intermediate of loramycin using continuous flow technology according to claim 1, Features: The reaction temperature is -15°C to 0°C.
9. The method for preparing a key intermediate of loramycin using continuous flow technology according to claim 1, Features: The reaction time is 10 to 50 seconds.
10. The method for preparing a key intermediate of loramycin using continuous flow technology according to any one of claims 1 to 9, It is characterized in that The following steps are also included: The resulting reaction solution is washed with acid, the pH is adjusted to neutral, and extracted with an organic solvent; The organic phase was concentrated, recrystallized, filtered and dried to obtain intermediate 5.
Citation Information
Cited By
Process for preparation of lolamicin
WO2026196313A1
